
    
      All participants will receive two injections of their randomized vaccine on Day 0 and Day 21,
      respectively.

      A subset of children and adolescents participants eligible for the antibody persistence
      evaluation were sampled 8 months after the first vaccination, they will also be proposed to
      receive the 2010-2011 Northern Hemisphere (NH) seasonal Trivalent Influenza Vaccine (TIV) 13
      months after the first vaccination. Immunogenicity response will be evaluated before
      vaccination and 21 days after vaccination with TIV, respectively.
    
  